Daré Bioscience Announces Return of Rights to Ovaprene®; Phase 3 Program Ongoing; Positive Interim Data and Grant Funding Position Asset for Value-Maximization

Core Viewpoint - Daré Bioscience has regained all rights to Ovaprene®, a hormone-free monthly intravaginal contraceptive, from Bayer HealthCare, which will enhance the company's strategic position as it advances through Phase 3 clinical trials [1][2][3] Group 1: Product Development and Clinical Trials - The Phase 3 program for Ovaprene is progressing with non-dilutive grant support, and the return of rights allows Daré to have full control over this late-stage asset [1][3] - Positive interim data from the Phase 3 trial, including consistent safety and tolerability, supports Ovaprene's potential as a meaningful alternative in women's health [3][4] - Enrollment for the ongoing Phase 3 study is expected to be completed in 2026, with operations continuing as planned [8] Group 2: Strategic Positioning and Market Potential - The consolidation of commercialization rights strengthens Daré's strategic position and allows for the evaluation of various partnership structures that reflect the value of Ovaprene [2][5] - Ovaprene is positioned to attract broad strategic interest across pharmaceutical and consumer health organizations due to its differentiation in the market [5][6] - The company aims to pursue attractive commercial pathways, including partnerships and non-traditional commercialization models, to maximize long-term economic benefits [6][8] Group 3: Company Mission and Focus - Daré Bioscience is dedicated to addressing gaps in women's health through innovative, science-based solutions, focusing on areas such as contraception, menopause, and vaginal health [10][11] - The company emphasizes the importance of rigorous clinical research and aims to accelerate the development of credible solutions for women's health needs [10][11]